A5006125844- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Diabetes Management and Research
- Neuroendocrine Tumor Research Advances
- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Body Composition Measurement Techniques
- Advanced Causal Inference Techniques
- Nutrition and Health in Aging
- Nutritional Studies and Diet
- Diet and metabolism studies
- Pancreatic and Hepatic Oncology Research
- Blood Pressure and Hypertension Studies
- Cardiac electrophysiology and arrhythmias
- Diabetes and associated disorders
- Cardiac pacing and defibrillation studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Adenosine and Purinergic Signaling
- Hormonal Regulation and Hypertension
- Potassium and Related Disorders
- Bariatric Surgery and Outcomes
- Erythropoietin and Anemia Treatment
Boehringer Ingelheim (Germany)
2016-2025
La Jolla Bioengineering Institute
2024
University of California, San Diego
2024
University of Mississippi Medical Center
2023
Jackson Memorial Hospital
2023
Université de Lorraine
2022
Inserm
2022
Boehringer Ingelheim (India)
2021
Boehringer Ingelheim (Australia)
2019-2021
Charité - Universitätsmedizin Berlin
2021
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes hypertension.Patients (N = 825) hypertension (mean seated systolic blood pressure [SBP] 130-159 mmHg diastolic [DBP] 80-99 mmHg) were randomized (double blind) to 10 mg or 25 placebo once daily for 12 weeks.At week 12, adjusted mean difference versus change from baseline 24-h SBP (ambulatory monitoring [ABPM]) was -3.44 (95% CI -4.78, -2.09) -4.16 (-5.50, -2.83) (both P < 0.001). At DBP...
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with and a reduced ejection fraction, without diabetes, but additional data are needed about effect drug on inpatient outpatient events that reflect worsening failure.We randomly assigned 3730 class II to IV an fraction ≤40% double-blind treatment placebo empagliflozin (10 mg once daily), addition recommended treatments failure, median 16 months. We prospectively collected information...
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient events.We randomly assigned 5988 class II through IV an fraction >40% to double-blind treatment placebo empagliflozin (10 mg once daily), addition usual therapy, a median 26 months. We prospectively collected information events reflecting worsening prespecified their analysis...
Aims To investigate the efficacy and tolerability of empagliflozin added to basal insulin‐treated type 2 diabetes. Methods Patients inadequately controlled [glycated haemoglobin ( HbA1c ) >7 ≤10% (>53 ≤86 mmol/mol)] on insulin (glargine, detemir, NPH were randomized 10 mg (n = 169), 25 155) or placebo 170) for 78 weeks. The baseline characteristics balanced among groups [mean 8.2% (67 mmol/mol), BMI 32.2 kg/m ]. dose was remain constant 18 weeks, then could be adjusted at...
Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular aortic distensibility (especially when accompanied by impaired glomerular function sodium retention) causes increases in cardiac filling pressures exertional dyspnoea despite...
Background: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure Reduced Ejection Fraction), empagliflozin reduced cardiovascular death or heart failure (HF) hospitalization and total HF hospitalizations, slowed the progressive decline kidney function patients with a ejection fraction, without diabetes. We aim to study effect of on outcomes across spectrum function. Methods: this prespecified analysis, were categorized by presence absence chronic disease...
Abstract Aims No therapy has shown to reduce the risk of hospitalization for heart failure across entire range ejection fractions seen in clinical practice. We assessed influence fraction on effect sodium–glucose cotransporter 2 inhibitor empagliflozin outcomes. Methods and results A pooled analysis was performed both EMPEROR-Reduced EMPEROR-Preserved trials (9718 patients; 4860 4858 placebo), patients were grouped based fraction: &lt;25% (n = 999), 25–34% 2230), 35–44% 1272), 45–54%...
We characterized the safety and tolerability of empagliflozin in patients with type 2 diabetes (T2DM) randomized 1:1:1 to placebo, 10 mg, or 25 mg clinical trials. Pooled data were analyzed from T2DM treated placebo (N = 4203), 4221), 4196) 15 phase I–III trials plus four extension studies. Adverse events (AEs) assessed descriptively participants who took at least one dose study drug. AE incidence rates per 100 patient-years calculated adjust for differences drug exposure between Total was...
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects empagliflozin exercise patient-reported outcomes in heart failure (HF) reduced preserved ejection fraction (EF), without type 2 diabetes (T2D), reporting, for first time, sodium-glucose co-transporter-2 inhibition EF (HFpEF).HF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or (>40%, 315, EMPERIAL-Preserved), T2D, were randomized to 10 mg placebo 12 weeks....
Abstract Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether benefits empagliflozin varied by baseline health status and how impacted patient-reported outcomes in patients with heart failure reduced ejection fraction. Methods results Health was assessed Kansas City Cardiomyopathy Questionnaires-clinical summary score (KCCQ-CSS). The influence KCCQ-CSS (analyzed tertiles) on effect major examined using Cox proportional hazards models. Responder analyses...
Mineralocorticoid receptor antagonists (MRAs) may be beneficial in reducing heart failure (HF) hospitalizations patients with HF preserved ejection fraction. The effect of sodium-glucose cotransporter 2 inhibitors fraction according to MRA background therapy has not been reported. aim this study was examine the empagliflozin users and nonusers EMPEROR-Preserved (Empagliflozin Outcome Trial Patients With Chronic Heart Failure Preserved Ejection Fraction) trial. Survival analyses were...
It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years therapy.In EMPEROR-Reduced (Empagliflozin Outcome Trials Chronic Heart Failure With Reduced Ejection Fraction) and EMPEROR-Preserved Preserved trials, patients with were randomly assigned (double-blind) to placebo or empagliflozin 10 mg/day for a median 16 26 months, respectively. At end 6799 (placebo 3381, 3418) prospectively withdrawn from treatment blinded manner, and,...
The EMPULSE trial evaluated the clinical benefit of empagliflozin versus placebo using stratified win ratio approach in 530 patients with acute heart failure (HF) after initial stabilization. We aim to elucidate how this method works and what it means, thereby giving guidance for use future trials.
OBJECTIVE To assess the effect of empagliflozin on bone fractures and mineral density in patients with type 2 diabetes pooled placebo-controlled trial data a head-to-head study versus glimepiride. RESEARCH DESIGN AND METHODS Pooled were analyzed from who randomized 1:1:1 to 10 mg, 25 or placebo phase I–III clinical trials. Data also EMPA-REG H2H-SU which received mg glimepiride as an add-on metformin for 104 weeks 104-week extension. Bone fracture adverse events (AEs) evaluated through...
Aims Heart failure (HF) is associated with considerable symptom burden and impairment in physical functioning quality of life. The sodium–glucose co‐transporter 2 inhibitor empagliflozin reduced the risk HF hospitalisation cardiovascular death patients type diabetes established disease EMPA‐REG OUTCOME trial, could potentially improve congestion symptoms exercise capacity HF. We describe designs EMPERIAL‐Preserved EMPERIAL‐Reduced trials chronic stable HF, or without diabetes. Methods are...
Differences in clinically important thresholds patient-reported outcomes measures such as the Kansas City Cardiomyopathy Questionnaire (KCCQ) remain less well-established patients with heart failure preserved ejection fraction (HFpEF) versus reduced (HFrEF).The purpose of this study was to estimate meaningful for improvement or deterioration KCCQ-Total Symptom Score (TSS) HFrEF HFpEF.This secondary analysis EMPERIAL program used anchor- and distribution-based approaches KCCQ-TSS using...
Sulfonylureas (SUs) are commonly used in the treatment of type 2 diabetes (T2DM), usually as second-line after failure metformin. However, SUs associated with poor durability, hypoglycemia and weight gain. Empagliflozin is a sodium glucose cotransporter (SGLT2) inhibitor development for T2DM. In Phase II/III trials, empagliflozin reduced hyperglycemia, body blood pressure, low incidence hypoglycemia. The aim this III study to compare effects SU glimepiride therapy patients T2DM inadequately...